TY - JOUR
T1 - Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases
AU - Donadon, Matteo
AU - Vauthey, Jean Nicolas
AU - Loyer, Evelyne M.
AU - Charnsangavej, Chusilp
AU - Abdalla, Eddie K.
PY - 2006/10/28
Y1 - 2006/10/28
N2 - In order to discuss the role of preoperative chemotherapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with lobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapy-induced liver injury.
AB - In order to discuss the role of preoperative chemotherapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with lobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapy-induced liver injury.
KW - Chemotherapy
KW - Colorectal liver metastases
KW - Resection
UR - http://www.scopus.com/inward/record.url?scp=33750988787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750988787&partnerID=8YFLogxK
U2 - 10.3748/wjg.v12.i40.6556
DO - 10.3748/wjg.v12.i40.6556
M3 - Article
C2 - 17072991
AN - SCOPUS:33750988787
SN - 1007-9327
VL - 12
SP - 6556
EP - 6558
JO - World journal of gastroenterology
JF - World journal of gastroenterology
IS - 40
ER -